Journal of Neural Transmission

, Volume 104, Issue 6–7, pp 649–660 | Cite as

Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease

  • J. Lan
  • D. H. Jiang
Parkinson's Disease and Allied Conditions


In this study a chronic cerebral iron-loaded model was established by feeding mice with high iron diet. Data indicated that brain iron concentrations were significantly increased in iron-fed mice compared with those of controls. A significant increase in oxidized glutathione (GSSG), decrease in total glutathione (oxidized and reduced glutathione, GSSG + GSH), and therefore increase in the GSSG/(GSSG + GSH) ratios were observed in iron-loaded mice. Hydroxyl radical (.OH) levels in striatum and brainstem were also significantly increased. Excessive iron alone did not change either dopamine (DA) or lipid peroxidation (LPO) concentrations in striatum. However, a single injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30mg/kg, i.p.) into the iron-loaded mice caused a great enhancement in all these biochemical abnormalities. These findings suggest that iron does induce oxidative stress, but not severely injury neurons per se. Excessive iron accumulation in the brain, however, is a potential risk for neuronal damage, which may promote by triggering factor(s). This supports the hypothesis that excessive cerebral iron may contribute to the aetiology of Parkinson's disease (PD).


Iron accumulation MPTP free radical damage PD 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams JD, Lauterberg BH, Mitchell JR (1983) Plasma glutathione and glutathione dissulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther 227: 749–754Google Scholar
  2. Aebi HE (1983) Catalase. In: Burgmeyer HU (ed) Methods of enzymatic analysis, 3rd ed, vol 3. Academic Press, New York, pp 273–286Google Scholar
  3. Althaus JS, Andrus PK, Williams CM, Von Voigtlander PF, Cazers AR, Hall ED (1993) The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury: reveal by tirilazad mesylate (U74006F). Mol Chem Neuropathol 20: 147–162Google Scholar
  4. Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 32: 114–118Google Scholar
  5. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical parkinsonism in rats. J Neurochem 57: 2133–2135Google Scholar
  6. Braughler JM, Chase RL, Pregenzer JF (1987) Oxidation of ferrous iron during peroxidation of lipid substrates. Biochem Biophys Acta 921: 457–464Google Scholar
  7. Cooper AJL, Pulsinelli WA, Duffy TE (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. J Neurochem 35: 1242–1245Google Scholar
  8. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989a) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830–1836Google Scholar
  9. Dexter DT, Jenner P, Marsden CD (1989b) Oxyferriscorbone elevates the total iron content of blood but not brain. Mov Disord 4: 176–182Google Scholar
  10. Dexter DT, Cater CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989c) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381–389Google Scholar
  11. Di Monte DA, Chan P, Sandy MS (1992) Glutathione in Parkinson's disease: a link between oxidative stress and mitochondria damage? Ann Neurol 32: S111–115Google Scholar
  12. Earle KM (1968) Studies in Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed tissue. J Neuropathol Exp Neurol 27: 1–14Google Scholar
  13. Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. In: Packer L (ed) Methods in enzymology, vol 105. Oxygen radicals in biological systems. Academic Press, New York, pp 114–121Google Scholar
  14. Floyd RA, Watson JJ, Wong PK (1984) Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J Biochem Biophys Methods 10: 221–235Google Scholar
  15. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (Mol Pharmacol Sect) 208: 273–286Google Scholar
  16. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative disease? J Neurochem 63: 793–807Google Scholar
  17. Gerlach M, Götz M, Dirr A, Kupsch A, Janetzky B, Oertel W, Sautter J, Schwarz J, Reichmann H, Riederer P (1996) Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Neurochem Int 28: 41–49Google Scholar
  18. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122Google Scholar
  19. Hallgren B, Sourander P (1958) The effect of age on the nonhaemin iron in the human brain. J Neurochem 3: 41–51Google Scholar
  20. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609–1623Google Scholar
  21. Heales SJ, Davies SE, Bates TE, Clark JB (1995) Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 20: 31–38Google Scholar
  22. Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345–348Google Scholar
  23. Jellinger K, Kienzl E, Rumperlmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 59: 1168–1171Google Scholar
  24. Jenner P (1991) Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand [Suppl] 136: 6–15Google Scholar
  25. Jenner P (1993) Altered mitochondria function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand [Suppl] 146: 6–13Google Scholar
  26. Kass GEN, Wright JM, Nicoatera P, Orrenius S (1988) The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys 260: 789–797Google Scholar
  27. Kim C, Speisky MB, Kharouba SN (1987) Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. J Chromatogr 386: 25–35Google Scholar
  28. Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343–346Google Scholar
  29. Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science 219: 979–980Google Scholar
  30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275Google Scholar
  31. Nicklas WJ, Vyas I, Heikilla RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetraphydrophyridine. Life Sci 36: 2503–2508Google Scholar
  32. Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310Google Scholar
  33. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989a) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520Google Scholar
  34. Riederer P, Konradi C, Hebenstreit G, Youdim MBH (1989b) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 126: 41–45Google Scholar
  35. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW (1992) Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 28: 645–649Google Scholar
  36. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW (1993) Infustion of iron into the rat substantia nigra: nigral pathology and dose dependent loss of dopaminergic markers. J Neurosci Res 35: 67–82Google Scholar
  37. Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 130: 82–94Google Scholar
  38. Singer TP, Castagnoli N Jr, Ramsay RR, Treor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49: 1–8Google Scholar
  39. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increase iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205Google Scholar
  40. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brain. J Neurochem 56: 978–982Google Scholar
  41. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128–130Google Scholar
  42. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86: 1398–1400Google Scholar
  43. Taylor E, Morgan E (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Dev Brain Res 55: 35–42Google Scholar
  44. Tietze F (1969) Enzymic method for quantitative determination of nanogram amount of total and oxidized glutathione. Anal Biochem 27: 502–522Google Scholar
  45. Uchiyama M, Mihara M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271–278Google Scholar
  46. Uitti RJ, Rajput AH, Rozdilsky B, Bickis M, Wollin T, Yuen WK (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains. Can J Neurol Sci 16: 310–314Google Scholar
  47. Werner P, Cohen G (1991) Intramitochondrial formation of oxidized glutathione during oxidation of benzylamine by monoamine oxidase. FEES Lett 280: 44–46Google Scholar
  48. Young VW, Perry TL, Krisman AA (1986) Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci Lett 63: 56–60Google Scholar
  49. Youdim MBH, Riederer P (1993) The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J Neural Transm [Suppl] 40: 57–67Google Scholar
  50. Zaleska MM, Floyd RA (1985) Regional lipid peroxidation in rat brain in vitro: possible role of endogenous iron. Neurochem Res 10: 397–410Google Scholar
  51. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62: 1097–1101Google Scholar
  52. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13: 290–296Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Lan
    • 1
  • D. H. Jiang
    • 1
  1. 1.Tianjin Neurological InstituteTianjin Medical University HospitalTianjinPeople's Republic of China

Personalised recommendations